Weekly insulin-semaglutide combination (IcoSema) provides greater blood sugar control than semaglutide alone
The COMBINE 2 trial shows switching to weekly IcoSema (insulin icodec + semaglutide) from semaglutide alone provides greater HbA1c reduction with similar hypoglycemia risk, though with unfavorable weight change.
Quick Facts
What This Study Found
IcoSema (weekly insulin icodec + semaglutide) achieved greater HbA1c reduction than semaglutide alone, with similar hypoglycemia risk and GI tolerability but unfavorable weight change, in T2DM patients inadequately controlled on GLP-1 RA therapy.
Key Numbers
COMBINE 2 trial data discussed; IcoSema showed greater HbA1c reduction vs semaglutide alone; similar hypoglycemia; unfavorable weight change with IcoSema.
How They Did This
Review of the COMBINE 2 randomized clinical trial comparing IcoSema to semaglutide in T2DM patients on GLP-1 RA therapy with or without oral glucose-lowering drugs.
Why This Research Matters
Many diabetes patients eventually need insulin despite GLP-1 therapy. A convenient once-weekly combination injection that improves glycemic control while maintaining the benefits of GLP-1 therapy simplifies treatment intensification and may improve adherence.
The Bigger Picture
Fixed-ratio combinations of insulin and GLP-1 agonists represent a pragmatic approach to treatment intensification that avoids the complexity of basal-bolus insulin regimens. Weekly dosing (vs. daily for current combinations) could significantly improve patient convenience.
What This Study Doesn't Tell Us
Review focused on one trial. Weight trade-off may limit adoption. Long-term outcome data needed. Comparison was against semaglutide alone, not basal-bolus insulin.
Questions This Raises
- ?Can exercise and dietary modifications offset the weight disadvantage of IcoSema?
- ?How does IcoSema compare to tirzepatide for intensification?
- ?Will once-weekly convenience improve long-term adherence enough to offset weight concerns?
Trust & Context
- Key Stat:
- Greater HbA1c reduction Weekly IcoSema combination outperformed semaglutide alone for blood sugar control with similar hypoglycemia risk
- Evidence Grade:
- Review of a randomized clinical trial (COMBINE 2). Strong evidence for efficacy comparison but limited to one trial.
- Study Age:
- Published in 2025; reviews the recently published COMBINE 2 trial.
- Original Title:
- COMBINE 2 is better than one: shaping the future of therapeutics in inadequately controlled type 2 diabetes.
- Published In:
- Expert review of clinical pharmacology, 18(5), 259-262 (2025)
- Authors:
- Popovic, Djordje S(7), Patoulias, Dimitrios(10), Koufakis, Theocharis(8), Papanas, Nikolaos
- Database ID:
- RPEP-13086
Evidence Hierarchy
Frequently Asked Questions
What is IcoSema?
IcoSema is a once-weekly injection combining insulin icodec (a long-acting weekly insulin) with semaglutide (a GLP-1 agonist) in a single pen. It simplifies treatment for people with type 2 diabetes who need both insulin and GLP-1 therapy.
Why might someone switch from semaglutide to IcoSema?
If semaglutide alone is not adequately controlling blood sugar, adding insulin is the next step. IcoSema provides this intensification in a single weekly injection rather than requiring separate daily insulin shots, improving convenience while achieving better glucose control.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-13086APA
Popovic, Djordje S; Patoulias, Dimitrios; Koufakis, Theocharis; Papanas, Nikolaos. (2025). COMBINE 2 is better than one: shaping the future of therapeutics in inadequately controlled type 2 diabetes.. Expert review of clinical pharmacology, 18(5), 259-262. https://doi.org/10.1080/17512433.2025.2516784
MLA
Popovic, Djordje S, et al. "COMBINE 2 is better than one: shaping the future of therapeutics in inadequately controlled type 2 diabetes.." Expert review of clinical pharmacology, 2025. https://doi.org/10.1080/17512433.2025.2516784
RethinkPeptides
RethinkPeptides Research Database. "COMBINE 2 is better than one: shaping the future of therapeu..." RPEP-13086. Retrieved from https://rethinkpeptides.com/research/popovic-2025-combine-2-is-better
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.